Mirati steps on the gas with KRAS inhibitor, looking to claim second approval behind Amgen's Lumakras
Amgen beat Mirati to the finish line with the first-ever approved KRAS inhibitor back in May. But Mirati’s picking up the pace and says it could be looking to carve out a space on the market by the end of the year with what it thinks is the better of the two data sets as monotherapy.
The FDA has granted breakthrough designation to Mirati’s adagrasib in non-small cell lung cancer patients with the KRAS-G12C mutation following prior therapy, the company said on Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.